Bio Solution Co

Bio Solution Co OCF Margin

The Operating Cash Flow Margin of Bio Solution Co (086820.KQ) as of Oct 22, 2026 is -8.63 %. In the previous year, Operating Cash Flow Margin was -17.74 % — a change of -51.36% (higher).

OCF Margin

-8.63 %

YoY

-51.36%

Last updated:

Operating Cash Flow Margin of Bio Solution Co is 2025 -8.63 % . Operating Cash Flow Margin of Bio Solution Co was 2024 -17.74 % . It decreases by -51.36% higher compared to the previous year.

The Bio Solution Co OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
9.75 KRW
Jan 1, 2019
-29.34 KRW
Jan 1, 2020
-21.77 KRW
Jan 1, 2021
0.71 KRW
Jan 1, 2022
-37.75 KRW
Jan 1, 2023
17.33 KRW
Jan 1, 2024
-17.74 KRW
Jan 1, 2025
-8.63 KRW
The Bio Solution Co OCF Margin history
YEAROCF MarginYoY
-8.63 %-51.36%
-17.74 %-202.34%
17.33 %-145.91%
-37.75 %-5,449.68%
0.71 %-103.24%
-21.77 %-25.79%
-29.34 %-400.94%
9.75 %-722.10%
-1.57 %-97.58%
-64.64 %-30.40%
-92.88 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio Solution Co Stock analysis

What does Bio Solution Co do? Bio Solution Co. Ltd. generates revenue through the manufacturing and distribution of cell therapy products and stem cell applied technologies. The company sells stem water, a cosmetic raw material containing human stem cells with whitening and anti-wrinkling effects, and keratinocyte medication for severe burns. Additionally, it offers chondrocyte therapy for arthritis treatment and develops human tissue models for toxicity and efficacy testing. The primary customers are cosmetic manufacturers and medical institutions seeking advanced therapeutic solutions. The firm's product portfolio includes stem water, keratinocyte medication, and chondrocyte therapy, all leveraging tissue engineering and stem cell technologies. These products target the cosmetic and medical sectors, with stem water appealing to the skincare market and keratinocyte and chondrocyte therapies serving medical applications. The company focuses on developing and commercializing cell-based solutions for both cosmetic and therapeutic uses. Bio Solution Co. Ltd. operates within the cell therapy and stem cell technology sector, providing specialized products that combine tissue engineering with stem cell applications. Its revenue streams are derived from the sale of cosmetic raw materials and medical therapeutics, with an emphasis on innovative, science-backed solutions for skin care and medical treatments. Bio Solution Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio Solution Co stock

Operating Cash Flow Margin of Bio Solution Co is -8.63 % in 2025.

Operating Cash Flow Margin of Bio Solution Co changed from -17.74 % to -8.63 %, representing a -51.36% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Bio Solution Co since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Bio Solution Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Bio Solution Co

All Key Metrics — Bio Solution Co